Inhalation is one of the TMA exposure routes for sensitization and subsequent asthma. The present work reported some characteristics after inhalation exposure of TMA aerosol. Brown Norway rats (n=8/group) were exposed, once a week from day 0 to day 63 with 40 mg/m 3 TMA or to day 70 with 4 mg/m 3 TMA in a nose-only system for 10 min. Enhanced pause (Penh, an index of airway resistance) was recorded in Buxco chambers overnight 12 hours). Sera were collected weekly for antibody analyses. For the group with 40mg/m 3 of TMA, specific IgE level was significantly increased after day 7 and reached the peak by day 49. By day 14 these rats developed early- (EAR) and late-phase airway responses (LAR) following exposure. For the group exposed to 4mg/m 3 of TMA, specific IgE level was significantly in-creased by day 21 and reached the peak by day 56; however, no obviously airway responses were noted. Two weeks after the final exposure the 4 mg/m 3 TMA exposed rats were challenged with 40 mg/m 3 TMA resulting in both an EAR and LAR response. The specific IgE levels for rats with high dose of TMA were greater than that with low dose of TMA. We conclude that high dose and short term inhalation exposure may induce specific IgE and airway responses; low dose and short term exposure can induce specific IgE production to establish sensitization, while the development of airway responses needs high dose of TMA for challenge.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.